Gene-Targeted Drugs Double Survival for Advanced Cancers — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Stephen Huff, a 29-year-old former professional baseball player diagnosed with stage 4 lung cancer, had over 300 genes sequenced through comprehensive genomic profiling, revealing an ALK alteration that let him receive the targeted drug alectinib — which shrank or eliminated his tumors within weeks.
- David Thomas at the Garvan Institute of Medical Research led a 2016 trial of comprehensive genomic profiling in nearly 4,000 patients with advanced cancers; over a third were matched to targeted drugs and lived almost twice as long as unmatched patients.
- Australia's nationwide program, launched in 2023 based on that trial, has enrolled over 26,000 people with poor-prognosis cancers, with approximately 48.5% receiving strong treatment recommendations.
- Pancreatic cancer patients matched to targeted treatments saw over 30% alive past five years, compared to 4% of unmatched patients, often through identification of responders to checkpoint-inhibitor immunotherapy.
- Japan, Germany, Norway, and Denmark have made comprehensive genomic profiling routinely available through their public healthcare systems, while the US has no national program and tests only about 1 in 4 advanced cancer patients due to awareness gaps and socioeconomic disparities.
- NHS England typically reports results for only 1 to 10 genes per patient despite sequencing hundreds, prompting oncologist Matthew Krebs and colleagues to advocate adding 30 'research genes' to identify candidates for clinical trials.
- New drugs including daraxonrasib (recently approved in the US for KRAS-mutated pancreatic cancer) and vorasidenib (for IDH1/IDH2-mutated gliomas) are expanding precision oncology's reach, alongside growing 'tumour-agnostic' approvals that allow prescription regardless of cancer location.
Why it matters: For patients genetically matched to targeted drugs, survival has roughly doubled in trials — and over 30% of matched pancreatic cancer patients are alive past five years, compared to 4% of unmatched ones. But access is sharply uneven: the US tests only 1 in 4 advanced-cancer patients, and the UK reports just 1 to 10 of hundreds of sequenced genes, making geography the decisive factor in who survives.
Ask SkimNews
